)
Edge12 Jun 2026
Set in Stone: The Story of Richemont
From a South African tobacco company to Cartier, a deep dive into how Richemont built one of the world's leading hard luxury empires.
Codexis
Codexis (CDXS) investor relations material
Codexis Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary2 Jun, 2026
Business overview and financial position
Focuses on scalable, sustainable enzymatic solutions for complex therapeutic manufacturing, including small molecule pharmaceuticals and RNA therapeutics.
Generates revenue from pharma biocatalysis and RNA manufacturing solutions, with a growing pipeline of higher-margin products.
Held $65 million in cash and equivalents as of March 31, 2026, with a projected cash runway through the end of 2027.
Pharma biocatalysis and customer engagement
Offers both off-the-shelf enzyme solutions and custom enzyme evolution projects for pharmaceutical manufacturing.
Pipeline includes 181 active programs, with strong customer engagement and maturing higher-margin products through 2030.
RNA therapeutics market and demand
RNA therapeutics, especially siRNA, are a rapidly growing modality with over 700 oligonucleotides in the pipeline and 180+ drug modalities in clinical phases.
Anticipated annual siRNA demand is expected to exceed 30,000 kg by the 2030s, driven by large patient indications.
Eight siRNA therapies are approved across multiple indications, including large populations such as hypercholesterolemia.
Drivers for higher-margin biocatalysis products
CapEx to meet 30,000 kg siRNA demand
Eliminating starter oligos in RNA synthesis
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Codexis
- Q1 2026 revenue doubled, net loss narrowed, and cash reserves support ongoing growth.CDXS
Q1 20267 May 2026 - Annual meeting to vote on directors, auditor, and executive pay, with board support for all proposals.CDXSProxy filing28 Apr 2026
- Key votes include director elections, auditor ratification, and executive pay approval.CDXSProxy filing28 Apr 2026
- 2025 revenue up 19% to $70.4M, Q4 profitable, 2026 outlook strong with $72–76M guidance.CDXSQ4 202511 Mar 2026
- ECO Synthesis platform drives RNA medicine manufacturing growth, targeting a $2B market by 2030.CDXSTD Cowen 46th Annual Health Care Conference3 Mar 2026
- Q2 revenue met expectations; guidance and double-digit growth outlook reaffirmed.CDXSQ2 20242 Feb 2026
- Enzymatic siRNA synthesis advances, driving new partnerships and strong revenue growth outlook.CDXSJefferies Global Healthcare Conference1 Feb 2026
- ECO Synthesis enables scalable, cost-effective siRNA production, driving growth and industry adoption.CDXS2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026
- Q3 2024 revenue up 38%, margin at 61%, net loss narrowed, cash runway extended to 2027.CDXSQ3 202417 Jan 2026
Next Codexis earnings date
Q2 202612 Aug, 2026
Codexis
Next Codexis earnings date
Q2 202612 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage